289 related articles for article (PubMed ID: 29685883)
1. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.
Claret L; Jin JY; Ferté C; Winter H; Girish S; Stroh M; He P; Ballinger M; Sandler A; Joshi A; Rittmeyer A; Gandara D; Soria JC; Bruno R
Clin Cancer Res; 2018 Jul; 24(14):3292-3298. PubMed ID: 29685883
[No Abstract] [Full Text] [Related]
2. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Gadgeel SM; Lukas RV; Goldschmidt J; Conkling P; Park K; Cortinovis D; de Marinis F; Rittmeyer A; Patel JD; von Pawel J; O'Hear C; Lai C; Hu S; Ballinger M; Sandler A; Gandhi M; Fehrenbacher L
Lung Cancer; 2019 Feb; 128():105-112. PubMed ID: 30642441
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
4. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
5. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
7. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
[TBL] [Abstract][Full Text] [Related]
8. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D; Reck M; Moro-Sibilot D; Mazieres J; Gadgeel S; Morris S; Cardona A; Mendus D; Ballinger M; Rittmeyer A; Peters S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737340
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
von Pawel J; Bordoni R; Satouchi M; Fehrenbacher L; Cobo M; Han JY; Hida T; Moro-Sibilot D; Conkling P; Gandara DR; Rittmeyer A; Gandhi M; Yu W; Matheny C; Patel H; Sandler A; Ballinger M; Kowanetz M; Park K
Eur J Cancer; 2019 Jan; 107():124-132. PubMed ID: 30562710
[TBL] [Abstract][Full Text] [Related]
10. Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.
Han K; Claret L; Sandler A; Das A; Jin J; Bruno R
BMC Cancer; 2016 Jul; 16():473. PubMed ID: 27412292
[TBL] [Abstract][Full Text] [Related]
11. ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.
Zou W; Yaung SJ; Fuhlbrück F; Ballinger M; Peters E; Palma JF; Shames DS; Gandara D; Jiang Y; Patil NS
JCO Precis Oncol; 2021 Nov; 5():827-838. PubMed ID: 34994614
[TBL] [Abstract][Full Text] [Related]
12. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Wu TW
Thorac Cancer; 2019 May; 10(5):1176-1181. PubMed ID: 30969033
[TBL] [Abstract][Full Text] [Related]
14. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
Marur S; Singh H; Mishra-Kalyani P; Larkins E; Keegan P; Sridhara R; Blumenthal GM; Pazdur R
Semin Oncol; 2018 Aug; 45(4):220-225. PubMed ID: 30391014
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
17. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Chen Y; Liu Q; Chen Z; Wang Y; Yang W; Hu Y; Han W; Zeng H; Ma H; Dai J; Zhang H
J Exp Clin Cancer Res; 2019 May; 38(1):193. PubMed ID: 31088500
[TBL] [Abstract][Full Text] [Related]
18. Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework.
Chan P; Marchand M; Yoshida K; Vadhavkar S; Wang N; Lin A; Wu B; Ballinger M; Sternheim N; Jin JY; Bruno R
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1171-1182. PubMed ID: 34270868
[TBL] [Abstract][Full Text] [Related]
19. A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab.
Shang X; Shi J; Wang X; Zhao C; Yu H; Wang H
Cancer Med; 2021 Sep; 10(18):6218-6226. PubMed ID: 34331414
[TBL] [Abstract][Full Text] [Related]
20. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Fehrenbacher L; von Pawel J; Park K; Rittmeyer A; Gandara DR; Ponce Aix S; Han JY; Gadgeel SM; Hida T; Cortinovis DL; Cobo M; Kowalski DM; De Marinis F; Gandhi M; Danner B; Matheny C; Kowanetz M; He P; Felizzi F; Patel H; Sandler A; Ballinger M; Barlesi F
J Thorac Oncol; 2018 Aug; 13(8):1156-1170. PubMed ID: 29777823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
